The current global pandemic COVID-19 challenges oncologists to reorganise cancer care. Cancer patients are more susceptible to infections and likely to get severe consequences compared with other patients. What can help us cope with the emergency effort represented by the management of cancer patients in the COVID-19 era, today and in the future?
The aim of the Vol II of this Research Topic is to offer a platform on which to gather available data from the “frontlines”, as the availability of such data will prove crucial to policymakers and medical practitioners alike. Through this platform, we would like to invite managers of cancer centers to gather and report data for the benefit of those who encountered or will encounter this infection. In particular, we believe that the main road to elaborate meaningful scientific evidence is represented by the collection of all the data on COVID-19 and cancer comorbidity that are and will become available in cancer centers.
New potential questions include but are not limited to the following:
1) What are the practical limitations when a patient is found to be positive for COVID-19 (before or) after a session of chemotherapy, immunotherapy and/or targeted therapies?
2) How should fragile patients with advanced disease receiving chemotherapy be treated when they are in areas heavily affected by the infection? What ethical and practical implications can there be?
3) What vaccination priority strategies should there be in cancer patients?
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The current global pandemic COVID-19 challenges oncologists to reorganise cancer care. Cancer patients are more susceptible to infections and likely to get severe consequences compared with other patients. What can help us cope with the emergency effort represented by the management of cancer patients in the COVID-19 era, today and in the future?
The aim of the Vol II of this Research Topic is to offer a platform on which to gather available data from the “frontlines”, as the availability of such data will prove crucial to policymakers and medical practitioners alike. Through this platform, we would like to invite managers of cancer centers to gather and report data for the benefit of those who encountered or will encounter this infection. In particular, we believe that the main road to elaborate meaningful scientific evidence is represented by the collection of all the data on COVID-19 and cancer comorbidity that are and will become available in cancer centers.
New potential questions include but are not limited to the following:
1) What are the practical limitations when a patient is found to be positive for COVID-19 (before or) after a session of chemotherapy, immunotherapy and/or targeted therapies?
2) How should fragile patients with advanced disease receiving chemotherapy be treated when they are in areas heavily affected by the infection? What ethical and practical implications can there be?
3) What vaccination priority strategies should there be in cancer patients?
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
